Form PTO-1449	Attorney's Docket No. 39780-1618P2C79	Application Serial No. 09/909,088
INFORMATION DISCLOSURE STATEMENT	Applicant(s) ASHKENAZI, et al.	
(use several sheets if necessary)	Filing Date: July 18, 2001	Group Art Unit: 1646

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
NJL	1.	8/21/90	4,950,647	Robins et al.			10/4/88
	2.	7/15/97	5,648,376	Strobel et al.			1/19/95
	3.	9/1/98	5,801,193	Ojo-Amaize et al.			4/15/97
	4.	10/6/98	5,817,306	Haskill et al.			6/7/95
	5.	09/28/99	5,958,403	Storm, et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES	Translation NO

OTHER DOCUMENTS
(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
NJL	6.	Abolhassani, M., "Antibacterial effect of borage (*Echium amoenum*) on *Staphylococcus aureus*," *Brazilian Journal of Infectious Diseases* 8:382-385 (2004).
	7.	Amirghofran, Z. et al., "*Echium amoenum* stimulate of lymphocyte proliferation and inhibit fo humoral antibody synthesis," *Im. J. Med. Sci.* 25:119-124 (2000).
	8.	Chapoval, A. I. et al., "Combination chemotherapy and IL-15 administration induces permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells," *J. Immunol.* 161:6977-6984 (1998).
	9.	Fung-Leung, et al., "Tepoxalin, A Novel Immunomodulatory Compound, Synergizes with CSA in Suppression of Graft-Versus-Host Reaction and Allogeneic Skin Graft Rejection", *Transplantation*, 60:362-368 (1995).
	10.	Gennari, R. et al., "Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance," *Annals of Surgery* 220:68-76 (1994).
	11.	Grabstein, K.H. et al., "Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor," *Science* 264:965-968 (1994)
	12.	Kasaian, M.T. et al., "IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity," *Immunity* 16:559-569 (2002).
	13.	Kirchner, G.I. et al., "Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application," *Br. J. Clin. Pharmacol.* 46:5-10 (1998).
	14.	Ma, H-L et al., "IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of INF-γ," *J. Immunol.* 171:608-615 (2003).
	15.	Naito, K. et al., "Macrophage factors which enhance the mixed leukocyte reaction initiated by dendritic cells," *J. Immunol.* 142:1834-1839 (1989).
	16.	Nastala, C.L. et al., "Recombinant IL-12 administration induces tumor regression in association with IFN-γ production," *J. Immunol.* 153:1697-1706 (1994).
	17.	Pahwa, R. et al. "Recombinant interleukin 2 therapy in severe combined immunodeficiency disease," *Proc. Natl. Acad. Sci. USA* 86:5069-5073 (1989).
	18.	Patterson, S. et al., "Human invariant NKT cells are required for effective in vitro alloresponses," *J. Immunol.* 175:5087-5094 (2005).

EXAMINER: NJL	DATE CONSIDERED: 1/21/07

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

Form PTO-1449	Attorney's Docket No. 39780-1618P2C79	Application Serial No. 09/909,088
INFORMATION DISCLOSURE STATEMENT	Applicant(s) ASHKENAZI, et al.	
(use several sheets if necessary)	Filing Date: July 18, 2001	Group Art Unit: 1646

NL	19.	Reddy, M.M. et al., "Interleukin 2 augmentation of natural killer cell activity in homosexual men with acquired immune deficiency syndrome," *Infect. Immunol.* 44:339-343 (1984).
	20.	Santoli, D. et al., "Autologous B lymphoblastoid cell lines and long-term cultured T cells as stimulators in the mixed lymphocyte reaction: analysis of the role of HLA class II antigens as stimulatory molecules," *J. Immunol.* 137:400-407 (1986).
	21.	Shim, et al., "Immunosuppressive Effects of Tautomycetin *in vivo* and *in vitro* via T cell-specific Apoptosis Induction," *Proc. Natl. Acad. Sci.*, USA, 99(16):10617-10622 (2002).
	22.	Tarr, P.E. et al., "Granulocyte-macrophage colony-stimulating factor and the immune system," *Med Oncol.* 13:133-140 (1996).
	23.	Toura, I. et al., "Cutting edge: Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide," *J. Immunol.* 163:2387-2391 (1999).
	24.	Tsavaris, N. et al., "Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes," *Br. J. Cancer* 87:21-27 (2002).

EXAMINER:	DATE CONSIDERED:
	12/1/07

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).